Delivering results. Confidently.
Expectant couples are often overwhelmed with information. They’re anxious. They’re worried. And they’re looking to you for answers. Our MaterniT21™ PLUS laboratory-developed test provides you and your patients with highly accurate information so you and your patients can make well informed decisions.
The MaterniT21 PLUS test is a noninvasive prenatal test that detects fetal chromosomal abnormalities; from common (trisomies 21, 18 and 13) to rare (sex aneuploidies, trisomies 16 and 22, and select microdeletions), all of the information that we report is clinically relevant.
We set the benchmark for noninvasive prenatal testing.
Our MaterniT21 PLUS test is designed to capitalize on its powerful technological capabilities. Using a versatile platform, we can now bring unprecedented information to you and your patients in a noninvasive prenatal test.
THE ENHANCED SEQUENCING SERIES, EXCLUSIVELY FOR THE MATERNIT21 PLUS TEST
Meaningful answers. Clear results. The power of MPS.
Massively parallel sequencing (MPS) is uniquely positioned to realize the promise of delivering relevant, enhanced information. Other methods lack the adaptability to efficiently add meaningful content.
We are proud to be your partner and deliver revolutionary content. This is merely a glimpse of all that we will bring you and your patients over time. You can count on Sequenom Laboratories to provide you with clarity, allowing you to provide the most advanced information available to your patients.
INNOVATION TRANSLATING TO PREMIUM CONTENT
In addition to content that you have come to rely on (chromosomes 21, 18, 13, X and Y), the Enhanced Sequencing Series debut includes:
- 22q deletion syndrome (DiGeorge)
- 5p (Cri-du-chat syndrome)
- 15q (Prader-Willi/Angelman syndromes
- 1p (1p36 deletion syndrome)
- Trisomy 16
- Trisomy 22
Findings of uncertain significance will not be reported.
There’s no room for maybe.
Other prenatal tests offer risk scores or unclear results. The MaterniT21 PLUS test reports test results as positive or negative, providing you and your patients with clear results.
Palomaki9,10, Bianchi13, Norton14, Zimmermann17.
Get an answer. The first time.
The MaterniT21 PLUS test has the lowest published and commercial non-reportable results rates to date. The unmatched performance of the MaterniT21 PLUS test means your patients can avoid retesting or potentially an unnecessary invasive procedure due to non-reportable results rates.
Clinical indications for testing.
Consistent with the American College of Obstetricians and Gynecologists / Society for Maternal-Fetal Medicine joint committee opinion, noninvasive prenatal testing is indicated for pregnant women at increased risk for fetal aneuploidy. The MaterniT21 PLUS test was validated with a population of pregnant women at increased risk for fetal chromosomal aneuploidies.
We offer this test for increased risk pregnancies with one or more of the following conditions:
- Advanced maternal age
- Personal or family history of chromosomal abnormalities
- Fetal ultrasound abnormality suggestive of aneuploidy
- Positive serum screening test
About the test.
What does it test for?
The MaterniT21 PLUS test reports on fetal chromosomal abnormalities; from common (trisomies 21, 18 and 13) to rare (sex aneuploidies, trisomies 16 and 22, and select microdeletions), all of the information that we report is clinically relevant. Sex chromosomal aneuploidies (X and Y) are reported in singleton pregnancies only. Sex chromosomal aneuploidies and microdeletions / duplications / additional trisomies will be reported as additional findings.
What specific sex chromosomal aneuploidies does it look for?
X, XXX, XYY, XXY
When can it be used?
Our test is indicated for use as early as ten weeks’ gestation.
What specific information is now included with the Enhanced Sequencing Series?
22q11.2 deletion syndrome (DiGeorge), Cri-du-chat syndrome (5p minus), Prader-Willi/Angelman syndrome, 1p36 deletion syndrome, Trisomy 16, and Trisomy 22.
What is the turnaround time?
The blood sample is sent to our laboratory and results are reported to you in approximately 7 business days from receipt of the sample in our lab.
How many tubes of blood do you need to run test?
2 x 10 mL in the mottled black/tan top blood collection tubes that are provided.
Are there any clinical restrictions that I should know about your test?
We can run samples from multifetal gestations in this pregnancy, egg donors, IVF patients -- essentially any pregnant woman at increased risk for fetal aneuploidies.
How well does it work?
The MaterniT21 PLUS test sensitivity ranges from 99.1% for Trisomy 21; >99.9% for Trisomy 18; and 91.7% for Trisomy 13, while maintaining a very low false positive rate (95% CI - 96.3–99.8%; 92.4-100%; and 59.7-99.6% respectively).
Does the American College of Obstetricians and Gynecologists (ACOG) support noninvasive prenatal testing?
Yes, the ACOG Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee issued a joint committee opinion supporting the use of noninvasive prenatal testing in pregnant women at high risk for fetal aneuploidies (Committee opinion no. 545: Noninvasive prenatal testing for fetal aneuploidy. 2012).
Prenatal provider materials.
Want to learn more about MaterniT21™ PLUS as well as all the rest of our tests? Click on this image below to view and/or download it digitally.
Prenatal Provider Brochure
Prenatal webinars for providers
22q and You: Implementing the MaterniT21 PLUS
Enhanced Sequencing Series into your practice